Roxadustat increases markers of calcification in patients with end-stage kidney disease: prospective cohort study
Authors' conclusion
Roxadustat treatment may increase iFGF23, SPP24, and calcification propensity in patients with ESKD when treating these patients for renal anemia.
Study context
- Population
- Patients with end-stage kidney disease (ESKD) treated for renal anemia187 analysed
- Participants
- 205 patients
- Exposure
- Roxadustat vs no roxadustat
- Roxadustatn = 92
- Controln = 95reference
- Outcome
- Change in the degree of hydroxyapatite (HAP) crystals deposition
- Follow-up
- 6 mo
Main finding
As reported in the abstract
Increase in deposition degree of HAP crystals
Observational data: associations, not effects.
Secondary outcomes
Calcification propensity · 6 mo
- Increased vs pre-treatment with roxadustat; no significant differences without roxadustat
- Roxadustat use was an independent risk factor for calcification propensity (linear regression)
Hematologic and mineral markers · 6 mo
- With roxadustat, increases vs pre-treatment in RBC counts, hematocrit, hemoglobin, calcium, total ferritin binding, iFGF23 and SPP24; no significant differences without roxadustat
Original publication
Roxadustat increases markers of calcification in patients with end-stage kidney disease: prospective cohort study. J Bone Miner Res. Published 27 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →